Table 1

Patient demographics and disease characteristics at baseline stratified by LDA (DAS28 ≤3.2) at weeks 52 or 48

EtanerceptEtanercept plus methotrexate
CharacteristicDAS28 ≤3.2 (n=67)DAS28 >3.2 (n=105)DAS28 ≤3.2 (n=115)DAS28 >3.2 (n=78)
Sex, n (%) female (male)46 (69) 21 (31)84 (80) 21 (20)81 (70) 34 (30)62 (80) 16 (20)
Age, mean years (SD)50.9 (15.0)53.5 (13.3)51.4 (12.9)52.6 (11.9)
Race, n (%) white (non-white)66 (99) 1 (1)103 (98) 2 (2)114 (99) 1 (1)76 (97) 2 (3)
RF positive, n (%)46 (69)79 (75)90 (78)61 (78)
DAS28 ESR, mean score (SD)6.4 (0.9)7.1 (0.8)6.5 (1.1)7.1 (0.8)
CDAI, mean score (SD)43.6 (12.0)49.4 (12.4)43.3 (12.3)52.1 (13.3)
ESR, mean mm/h (SD)30.6 (20.9)45.1 (22.3)37.2 (23.4)44.3 (25.9)
TJC, mean no (SD)17.1 (6.4)19.0 (6.5)16.5 (6.9)20.4 (6.4)
SJC, mean no (SD)14.4 (5.7)15.9 (5.7)13.3 (5.2)17.3 (6.3)
HAQ-DI, mean score (SD)1.5 (0.6)1.9 (0.6)1.6 (0.6)1.9 (0.6)
  • CDAI, clinical disease activity index; DAS28 ESR, disease activity score based on 28 joints with ESR as marker of inflammation; ESR, erythrocyte sedimentation rate; HAQ-DI, health assessment questionnaire disability index; LDA, low disease activity; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count.